These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15479865)

  • 21. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunology of viral co-infections with HIV.
    Northfield JW; Harcourt G; Lucas M; Klenerman P
    Arch Immunol Ther Exp (Warsz); 2005; 53(1):3-12. PubMed ID: 15761372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignancy and biologic therapy in rheumatoid arthritis.
    Askling J; Bongartz T
    Curr Opin Rheumatol; 2008 May; 20(3):334-9. PubMed ID: 18388527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biological treatment of rheumatic diseases].
    Procházková L; Böhmová J; Soucek M
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rheumatic symptoms in patients with human immunodeficiency virus are related to levels of tumor necrosis factor-alpha but not to viral load.
    de Filippis LG; Scibilia G; Caliri A; Morgante S; Arena A; Todaro G; Bonina L; Lo Gullo R; Bagnato GF
    Int J Tissue React; 2005; 27(1):9-13. PubMed ID: 15847100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor necrosis factor-alpha therapy and potential cancer inhibition.
    Williams GM
    Eur J Cancer Prev; 2008 Apr; 17(2):169-77. PubMed ID: 18287875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis.
    Askling J; Dixon W
    Curr Opin Rheumatol; 2008 Mar; 20(2):138-44. PubMed ID: 18349742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infection risk associated with anti-TNF-α agents: a review.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
    Expert Opin Drug Saf; 2015 Apr; 14(4):571-82. PubMed ID: 25630559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
    Wendling D; Di Martino V; Herbein G
    J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
    [No Abstract]   [Full Text] [Related]  

  • 34. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infectious complications of biological therapy.
    Haroon N; Inman RD
    Curr Opin Rheumatol; 2009 Jul; 21(4):397-403. PubMed ID: 19412102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?
    Ramos-Casals M
    Nat Rev Rheumatol; 2010 Nov; 6(11):618-20. PubMed ID: 21037559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk.
    Khasnis AA; Calabrese LH
    Semin Arthritis Rheum; 2010 Oct; 40(2):147-63. PubMed ID: 19914686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases.
    Borchers AT; Leibushor N; Cheema GS; Naguwa SM; Gershwin ME
    J Autoimmun; 2011 Dec; 37(4):273-88. PubMed ID: 21907543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature.
    Fotiadou C; Lazaridou E; Ioannides D
    J Eur Acad Dermatol Venereol; 2011 Apr; 25(4):471-4. PubMed ID: 20561122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis infection in immunocompromised patients.
    Gitnick G
    Gastroenterol Clin North Am; 1994 Sep; 23(3):515-21. PubMed ID: 7989092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.